Article information
Full text is only aviable in PDF
References
[1.]
J. Autier, B. Escudier, J. Wechsler, A. Spatz, C. Robert.
Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
Arch Dermatol, 144 (2008), pp. 886-892
[2.]
C. Robert, C. Mateus, A. Spatz, J. Wechsler, B. Escudier.
Dermatologic symptoms associated with the multikinase inhibitor sorafenib.
J Am Acad Dermatol, 60 (2009), pp. 299-305
[3.]
L. Liu, Y. Cao, C. Chen, X. Zhang, A. McNabola, D. Wilkie, et al.
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Cancer Res, 66 (2006), pp. 11851-11858
[4.]
C. Robert, C. Mateus, A. Spatz, J. Wechsler, B. Escudier.
Dermatologic symptoms associated with the multikinase inhibitor sorafenib.
J Am Acad Dermatol, 60 (2009), pp. 299-305
[5.]
L. Hueso, O. Sanmartín, E. Nagore, R. Botella-Estrada, C. Requena, B. Llombart, et al.
Eritema acral inducido por quimioterapia: estudio clínico e histopatológico de 44 casos.
Actas Dermosifiliogr, 99 (2008), pp. 281-290
[6.]
E. Nagore, A. Insa, O. Sanmartín.
Antineoplastic therapyinduced palmar plantar erythrodysesthesia (“hand-foot”) syndrome. Incidence, recognition and management.
Am J Clin Dermatol, 1 (2000), pp. 225-234
[7.]
C.H. Yang, W.C. Lin, C.K. Chuang, Y.C. Chang, S.T. Pang, Y.C. Lin, et al.
Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy.
Br J Dermatol, 158 (2008), pp. 592-596
Copyright © 2009. Academia Española de Dermatología y Venereología and Elsevier España, S.L.
